Our previous study demonstrated that manganese oxide nanoparticles (MnO NP) selectively destroyed U-87MG and U251 human glioblastoma cells in vitro. MnO NP were synthesized and studied by electron microscopy. Their antitumor properties were studied in vivo on the model of immunodeficient SCID mice with subcutaneous xenografts of U-87MG human glioblastoma. The mice were injected subcutaneously with MnO NP in doses of 0.96 and 1.92 mg/kg (calculated for Mn) 3 days a week over 3 weeks. In was shown that MnO NP in these doses significantly suppressed the growth of U-87MG glioblastoma xenografts: on day 21 from the start of the treatment, the tumor growth inhibition index was 61.1 and 99.22%, respectively. These results indicate the necessity of the further studies of MnO NP as a potential oncolytic agent for the therapy of human glioblastomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011;6(9):e24374. doi: https://doi.org/10.1371/journal.pone.0024374
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008;14(5):1310-1316.
Frosina G. Limited advances in therapy of glioblastoma trigger re-consideration of research policy. Crit. Rev. Oncol. Hematol. 2015;96(2):257-261.
Hanley C, Layne J, Punnoose A, Reddy KM, Coombs I, Coombs A, Feris K, Wingett D. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology. 2008;23(19):295103. doi: https://doi.org/10.1088/0957-4484/19/29/295103
Hao Y, Wang L, Zhang B, Zhao H, Niu M, Hu Y, Zheng C, Zhang H, Chang J, Zhang Z, Zhang Y. Multifunctional nanosheets based on folic acid modified manganese oxide for tumor-targeting theranostic application. Nanotechnology. 2016;27(2):025101. doi: https://doi.org/10.1088/0957-4484/27/2/025101
Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastomamultiforme: Current state-of-the-art. J. Control. Release. 2016;227:23-37.
Konarev PV, Petoukhov MV, Volkov VV, Svergun DI. ATSAS 2.1, a program package for small-angle scattering data analysis. J. Appl. Cryst. 2006;39:277-286.
Król A, Pomastowski P, Rafińska K, Railean-Plugaru V, Buszewski B. Zinc oxide nanoparticles: Synthesis, antiseptic activity and toxicity mechanism. Adv. Colloid Interface Sci. 2017;249:37-52.
Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008;5(4):496-504.
Nam J, Won N, Bang J, Jin H, Park J, Jung S, Jung S, Park Y, Kim S. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv. Drug Deliv. Rev. 2013;65(5):622-648.
Raliya R, Singh Chadha T, Haddad K, Biswas P. Perspective on nanoparticle technology for biomedical use. Curr. Pharm. Des. 2016;22(17):81-90.
Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin. Drug Deliv. 2010;7(9):1063-1077.
Razumov IA, Zav’yalov EL, Troitskii SY, Romashchenko AV, Petrovskii DV, Kuper KE, Moshkin MP. Selective cytotoxicity of manganese nanoparticles against human glioblastoma cells. Bull. Exp. Biol. Med. 2017;163(4):561-565.
Schladt TD, Schneider K, Shukoor MI, Natalio F, Bauer H, Tahir MN, Weber S, Schreiber LM, Schröder HC, Müller WEG, Tremel W. Highly soluble multifunctional MnO nanoparticles for simultaneous optical and MRI imaging and cancer treatment using photodynamic therapy. J. Mater. Chem. 2010;20:8297-8304.
Smith L, Kuncic Z, Ostrikov K, Kumar S. Nanoparticles in cancer imaging and therapy. J. Nanomater. 2012;9:891318. doi: https://doi.org/10.1155/2012/891318
Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989;24(3):148-154.
Troitskii SYu, Chuvilin AL, Kochubei DI, Novgorodov BN, Kolomiichuk VN, Likholobov VA. Structure of polynuclear palladium(II) hydroxocomplexes formed upon alkaline hydrolysis of palladium(II) chloride complexes. Russ. Chem. Bull. 1995;44(10):1822-1826.
Vinardell MP, Mitjans M. Antitumor activities of metal oxide nanoparticles. Nanomaterials. 2015;5(2):1004-1021.
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Release. 2015;200:138-157.
Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y, Peng R, Liu Z. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat. Commun. 2017;8(1):902. doi: https://doi.org/10.1038/s41467-017-01050-0
Zavjalov EL, Razumov IA, Gerlinskaya LA, Romashchenko AV. In vivo MRI visualization of growth and morphology in the orthotopic xenotrasplantation U87 glioblastoma mouse SCID model. Russ. J. Genet. Appl. Res. 2016;6(4):448-453.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 3, pp. 191-196, September, 2020
Rights and permissions
About this article
Cite this article
Razumov, I.A., Troitskii, S.Y., Solov’eva, O.I. et al. Manganese Oxide Nanoparticles Inhibit the Growth of Subcutaneous U-87MG Glioblastoma Xenografts in Immunodeficient Mouse. Bull Exp Biol Med 170, 148–153 (2020). https://doi.org/10.1007/s10517-020-05021-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-05021-2